Kite, a Gilead Sciences company, recently reported new analysis showing that its CAR T therapy Yescarta delivers consistent ...

Gilead Sciences stock has seen its fair value estimate edge down only slightly, from about $130.83 to $130.63, even as the discount rate nudged up from roughly 7.26% to 7.29% and long term revenue ...

A group often forgotten about in the discussion of HIV – despite research pointing to an ongoing crisis – is Black women in ...

Citi Annual Global Healthcare Conference 2025 December 2, 2025 11:15 AM ESTCompany ParticipantsAndrew Dickinson - ...

An updated Canadian guideline on HIV prevention addresses the expanding range of medications available to reduce the risk of ...

Debt Management: Gilead Sciences's debt-to-equity ratio is below the industry average. With a ratio of 1.16, the company ...

News Is Out hosts an online panel discussion with Gilead’s Choose U ambassadors sharing stories of resilience, empowerment ...

GILD's HIV strength, new approvals, and rising estimates set it apart as it edges past a challenged rival in growth prospects.

Evercore 8th Annual Healthcare Conference December 3, 2025 10:50 AM ESTCompany ParticipantsDietmar Berger - Chief ...

Gilead Sciences (GILD) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...

The first deliveries of lenacapavir to the African continent represent a turning point in the fight against HIV.

Despite advances in HIV treatment, the epidemic still disproportionately affects Black communities in the South, particularly ...